Earnings Call Summary | ENDRA Life Sciences(NDRA.US) Q1 2024 Earnings Conference
Earnings Call Summary | ENDRA Life Sciences(NDRA.US) Q1 2024 Earnings Conference
The following is a summary of the ENDRA Life Sciences Inc. (NDRA) Q1 2024 Earnings Call Transcript:
以下是ENDRA生命科學公司（NDRA）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
ENDRA Life Sciences has reported a decreased operating expense to $2.8 million in Q1 2024, primarily due to reduced research and development expenses.
The company's net loss stood at $2.8 million, or $0.26 per share, an improvement from a net loss of $2.9 million or $0.93 per share in Q1 2023.
The company's cash and cash equivalents totalled $1.1 million as of March 31, 2024.
ENDRA生命科學報告稱，2024年第一季度的運營支出減少至280萬美元，這主要是由於研發費用減少。
該公司的淨虧損爲280萬美元，合每股虧損0.26美元，較2023年第一季度的淨虧損290萬美元或每股虧損0.93美元有所改善。
截至2024年3月31日，該公司的現金和現金等價物總額爲110萬美元。
Business Progress:
業務進展：
ENDRA Life Sciences is targeting new clinical research sites and markets to gather clinical evidence for the TAEUS system.
Regular interactions are being held with the FDA to meet the clinical requirements of their TAEUS systems De Novo application.
They have installed the first TAEUS system in the United Kingdom and have expanded their global intellectual property portfolio with the issuance of eight additional patents.
Opportunities for collaborations and strategic growth beyond liver disease are being actively explored.
ENDRA Life Sciences正在瞄準新的臨床研究場所和市場，爲TAEUS系統收集臨床證據。
定期與美國食品藥品管理局進行互動，以滿足其TAEUS系統De Novo應用的臨床要求。
他們已經在英國安裝了第一個TAEUS系統，並通過另外八項專利的頒發擴大了其全球知識產權組合。
正在積極探索肝病以外的合作和戰略增長機會。
More details: ENDRA Life Sciences IR
更多詳情： ENDRA 生命科學 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。